NCT03667703View on ClinicalTrials.gov

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 10, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Congenital Heart DiseaseUpper Gastrointestinal BleedingStress UlcerInfection
Interventions
DRUG

Famotidine

Patients will be randomized to either receive a placebo or famotidine (study drug).

DRUG

Placebo

Patients will be randomized to either receive a placebo or famotidine (study drug).

Trial Locations (1)

02115

Boston Children's Hospital, Boston

All Listed Sponsors
collaborator

The Gerber Foundation

OTHER

lead

Boston Children's Hospital

OTHER

NCT03667703 - Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease | Biotech Hunter | Biotech Hunter